Edwards Lifesciences Corp (EW)vsHyperfine Inc (HYPR)
EW
Edwards Lifesciences Corp
$85.88
-1.70%
HEALTHCARE · Cap: $49.01B
HYPR
Hyperfine Inc
$1.47
-8.00%
HEALTHCARE · Cap: $158.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 41021% more annual revenue ($6.30B vs $15.33M). EW leads profitability with a 17.4% profit margin vs -226.9%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
HYPR
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.6%
Fair Value
$252.36
Current Price
$85.88
$166.48 discount
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Revenue surging 82.6% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 82.6% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
EW profiles as a growth stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.42 — expect wider price swings.
HYPR is growing revenue faster at 82.6% — sustainability is the question.
HYPR generates stronger free cash flow (-9M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 23/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a leading medical technology innovator that has revolutionized imaging diagnostics with the introduction of the first FDA-cleared portable MRI system. This groundbreaking solution enhances accessibility to imaging directly at the point of care, thereby improving patient outcomes and expediting clinical decision-making. By prioritizing cost efficiency and convenience, Hyperfine is well-positioned to capitalize on burgeoning market opportunities, making it an appealing investment for institutional investors interested in transformative healthcare advancements.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?